Refractory vertebral sarcoidosis responding to infliximab

Journal of Clinical Rheumatology

Volumn 14, Issue 4, 2008, Pages 238-240

  Garg, Sanjay ^a   Garg, Kusum ^b   Altaf, Mujeeb ^c   Magaldi, John A ^d  

^a DUKE UNIVERSITY   (United States)

^b Cape Fear Valley Hospital   (United States)

^c ST MARY S HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infliximab; Sarcoidosis; Tumor necrosis factor ; Vertebral

Indexed keywords

GABAPENTIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TIAGABINE; TOPIRAMATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BONE PAIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; GIANT CELL; GRANULOMA; HUMAN; LEG PAIN; LOW BACK PAIN; LUMBAR SPINE; LUNG HILUS; LUNG NODULE; LUNG SARCOIDOSIS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PRIORITY JOURNAL; SARCOIDOSIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VERTEBRAL SARCOIDOSIS; WEIGHT REDUCTION; DRUG ANTAGONISM; PATHOLOGY; SPINE DISEASE;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; SARCOIDOSIS; SPINAL DISEASES; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149264706     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318181b45a     Document Type: Article

References (17)

1. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155:1665-1669.
2. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227-232.
3. Pritchard C, Nadarajah K. Tumour necrosis factor-α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63:318 -320.
4. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70 -74.
5. Mallbris L, Ljungberg A, Hedblad M, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-α therapy. J Am Acad Dermatol. 2003;48:290 -293.
6. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol. 2003;2:413-414.
7. Roberts SD, Wilkes DS, Burgett RA, et al. Refractory sarcoidosis responding to infliximab. Chest. 2003;124:2028 -2031.
8. Katz JM, Bruno MK, Winterkorn JM, et al. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol. 2003;60:426-430.
9. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660 -1661.
10. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med. 2001; 135:27-31.
11. Doty JD, Mazur JE, Judson MA, et al. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064 -1071.
12. Usui Y, Kaiser ED, See RF, et al. Update of ocular manifestations in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:167-175.
13. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003;21:241-248.
14. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 1990;115:36-42.
15. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med. 2001;345:1098 -1104.
16. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am J Respir Crit Care Med. 2003;167:1279 -1282.
17. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum. 2002;46: 3151-3158.